Policy

Poland to ban MON810 maize
Enlarge image

BusinessPoland

Poland to ban MON810 maize

16.04.2012 - The Polish government is to ban Monsanto's MON810 maize making it the seventh in the club of EU countries to stop cultivation of the GM crop.

Warsaw – The move follows protests in Warsaw last month by around 1,500 beekeepers and anti-GM protesters who dumped thousands of dead bees on the steps of the Ministry of Agriculture. Agriculture Minister Marek Sawicki has announced that the government would implement a ban on the cultivation of the genetically modified MON 810 maize. The minister claimed the pollen might be responsible for a host of health problems and may even be the cause of the dwindling bee population. The government now wants to pass a law that circumvents the need to obtain EU approval for a ban on any GMO crops. Revised Polish regulations would stipulate that the ban may be implemented and that it will suffice simply to notify the European Commission of the matter. “We are pleasantly surprised that the government is looking for a way of actually implementing the ban,” said Greenpeace spokesman Jacek Winiarski after having a discussion with governmental representatives. If Poland implements the ban, it will follow in the footsteps of Austria, France, Germany, Greece, Hungary and Luxembourg which have all banned the cultivation of MON 810 at different stages, saying it threatens biodiversity.

http://www.european-biotechnology-news.com/news/news/2012-02/poland-imposes-ban-on-gmos.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.39 CHF21.87%
  • THERAMETRICS0.07 CHF16.67%
  • SANTHERA97.50 CHF5.98%

FLOP

  • 4SC0.78 EUR-8.24%
  • ADDEX3.36 CHF-5.62%
  • BIOFRONTERA1.95 EUR-2.50%

TOP

  • CYTOS0.39 CHF77.3%
  • ADDEX3.36 CHF44.2%
  • BB BIOTECH253.50 EUR28.1%

FLOP

  • ACTELION99.25 CHF-16.3%
  • BIOFRONTERA1.95 EUR-15.2%
  • 4SC0.78 EUR-13.3%

TOP

  • SANTHERA97.50 CHF2355.9%
  • BB BIOTECH253.50 EUR100.5%
  • FORMYCON12.40 EUR61.0%

FLOP

  • CYTOS0.39 CHF-88.2%
  • 4SC0.78 EUR-53.3%
  • MOLOGEN5.79 EUR-50.2%

No liability assumed, Date: 27.01.2015